Exact Mass: 532.2308356
Exact Mass Matches: 532.2308356
Found 500 metabolites which its exact mass value is equals to given mass value 532.2308356,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Nomilinic acid
Nomilinic acid is found in citrus. Nomilinic acid is a constituent of grapefruit seeds
Austalide E
Austalide E is a metabolite of Aspergillus ustus. Metabolite of Aspergillus ustus.
Austalide D
Austalide D is a metabolite of Aspergillus ustu Metabolite of Aspergillus ustus.
Ponatinib
C29H27F3N6O (532.2198328000001)
Ponatinib is a Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012 (DB08901). L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
Dehydroandrographolide succinate
3-[3-[4-[5-(2-Carboxyethyl)-2-hydroxyphenyl]-1,4-bis(carboxymethylamino)butyl]-4-hydroxyphenyl]propanoic acid
PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0)
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0)
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0)
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Dehydroandrographolidesuccinate
Dehydroandrographolide succinate, extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect[1]. Dehydroandrographolide succinate, extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect[1].
[3R-(3alpha,5beta,5aalpha,6alpha,7alpha,9alpha,9aalpha,10R*)]-Octahydro-5a-(hydroxymethyl)-2,2,9-trimethyl-, 6,7,10-triacetate 5-benzoate 2H-3,9a-methano-1-benzoxepin-5,6,7,10-tetrol
Ejap 10
[3R-(3alpha,5beta,5aalpha,6alpha,9beta,9aalpha,10R*)]-5a-[(Acetyloxy)methyl]octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzoxepin-5,6,9,10-tetrol 5,10-diacetate 6-benzoate
Rzedowskin A
[3R-(3alpha,4beta,5alpha,5aalpha,6alpha,9beta,9aalpha,10R*)]-Octahydro-2,2,5a,9-tetramethyl-, 4,5,10-triacetate 6-benzoate 2H-3,9a-methano-1-benzoxepin-4,5,6,9,10-pentol
(1S,4S,5S,6R,7R,9S,10S)-9-benzoyloxy-1,6,15-triacetoxy-4-hydroxy-dihydro-beta-agarofuran|9-Benzoyl,1,6,14-tri-Ac-(1alpha,4beta,6beta,9beta)-1,4,6,8,14-Pentahydroxydihydro-beta-agarofuran
bistratamide F
A homodetic cyclic peptide that consists of L-threonine and L-valine and L-serine as the amino acid residues cyclised via amide bonds. It is isolated from Lissoclinum bistratum and exhibits antitumour activity against the human colon tumour cell line
4-[(beta-D-glucopyranosyl)oxy]-2-(hydroxymethyl)-3-(3-methylbut-2-en-1-yl)phenyl beta-D-glucopyranoside|clemomandshuricoside C
(9R)-2beta,9-dihydroxymegastigma-4,7-dien-3-one 9-O-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranoside
6beta,9beta,14-Triacetoxy-1alpha-benzoyloxy-4beta-hydroxydihydro-beta-agarofuran
(6S,7R,Ra)-3-phenylacrylic acid 2,3,10,11,12-pentamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cycloocten-1-yl ester|neglschisandrin A
(6R,9R)-3-oxo-alpha-ionol-9-O-beta-D-glucopyranosyl(1->2)-beta-D-glucopyranoside
(1S,4S,5S,6R,7R,9S,10S)-1,6,15-triacetoxy-9-benzoyloxy-4-hydroxy-8-oxo-dihydro-beta-agarofuran
(1alpha,2alpha,8beta,9beta)-2,8,14-tris(acetyloxy)-9-(benzoyloxy)-1-hydroxydihydro-beta-agarofuran|rel-5a-[(acetyloxy)methyl]octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzoxepin-4,5,6,7-tetrol 4,7-diacetate 5-benzoate
12-Oxo-2beta,3beta-di-O-acetyl-5beta,11alpha-dihydroxybufalin
12-hydroxyamoorastatone|12alpha-hydroxyamoorastatone|isochuanliansu
His Val Tyr Asp
Asn Asp Glu Arg
C28H36O10_2-Hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0~1,17~.0~4,16~.0~6,14~.0~8,12~]tricosa-6(14),7,12-trien-18-yl acetate
Ala Ala Trp Trp
Ala Glu Gln Trp
Ala Glu Trp Gln
Ala Gln Glu Trp
Ala Gln Trp Glu
Ala Trp Ala Trp
Ala Trp Glu Gln
Ala Trp Gln Glu
Ala Trp Trp Ala
Cys Lys Pro Trp
Cys Lys Trp Pro
Cys Pro Lys Trp
Cys Pro Gln Trp
Cys Pro Trp Lys
Cys Pro Trp Gln
Cys Gln Pro Trp
Cys Gln Trp Pro
Cys Trp Lys Pro
Cys Trp Pro Lys
Cys Trp Pro Gln
Cys Trp Gln Pro
Asp Asp Gln Arg
Asp Asp Arg Gln
Asp Glu Asn Arg
Asp Glu Arg Asn
Asp Gly Arg Trp
C23H32N8O7 (532.2393841999999)
Asp Gly Trp Arg
C23H32N8O7 (532.2393841999999)
Asp His Val Tyr
Asp His Tyr Val
Asp Asn Glu Arg
Asp Asn Arg Glu
Asp Asn Val Trp
Asp Asn Trp Val
Asp Gln Asp Arg
Asp Gln Arg Asp
Asp Arg Asp Gln
Asp Arg Glu Asn
Asp Arg Gly Trp
C23H32N8O7 (532.2393841999999)
Asp Arg Asn Glu
Asp Arg Gln Asp
Asp Arg Trp Gly
C23H32N8O7 (532.2393841999999)
Asp Val His Tyr
Asp Val Asn Trp
Asp Val Trp Asn
Asp Val Tyr His
Asp Trp Gly Arg
C23H32N8O7 (532.2393841999999)
Asp Trp Asn Val
Asp Trp Arg Gly
C23H32N8O7 (532.2393841999999)
Asp Trp Val Asn
Asp Tyr His Val
Asp Tyr Val His
Glu Ala Gln Trp
Glu Ala Trp Gln
Glu Asp Asn Arg
Glu Asp Arg Asn
Glu Glu Lys Gln
Glu Glu Gln Lys
Glu Glu Gln Gln
C20H32N6O11 (532.2128961999999)
Glu Phe His Thr
Glu Phe Thr His
Glu His Phe Thr
Glu His Thr Phe
Glu Lys Glu Gln
Glu Lys Gln Glu
Glu Asn Asp Arg
Glu Asn Arg Asp
Glu Gln Ala Trp
Glu Gln Glu Lys
Glu Gln Glu Gln
C20H32N6O11 (532.2128961999999)
Glu Gln Lys Glu
Glu Gln Gln Glu
C20H32N6O11 (532.2128961999999)
Glu Gln Trp Ala
Glu Arg Asp Asn
Glu Arg Asn Asp
Glu Thr Phe His
Glu Thr His Phe
Glu Trp Ala Gln
Glu Trp Gln Ala
Phe Glu His Thr
Phe Glu Thr His
Phe Phe Gly Tyr
Phe Phe Tyr Gly
Phe Gly Phe Tyr
Phe Gly Tyr Phe
Phe His Glu Thr
Phe His Met Val
Phe His Thr Glu
Phe His Val Met
Phe Met His Val
Phe Met Val His
Phe Thr Glu His
Phe Thr His Glu
Phe Val His Met
Phe Val Met His
Phe Tyr Phe Gly
Phe Tyr Gly Phe
Gly Asp Arg Trp
C23H32N8O7 (532.2393841999999)
Gly Asp Trp Arg
C23H32N8O7 (532.2393841999999)
Gly Phe Phe Tyr
Gly Phe Tyr Phe
Gly Arg Asp Trp
C23H32N8O7 (532.2393841999999)
Gly Arg Trp Asp
C23H32N8O7 (532.2393841999999)
Gly Trp Asp Arg
C23H32N8O7 (532.2393841999999)
Gly Trp Arg Asp
C23H32N8O7 (532.2393841999999)
Gly Tyr Phe Phe
His Asp Val Tyr
His Asp Tyr Val
His Glu Phe Thr
His Glu Thr Phe
His Phe Glu Thr
His Phe Met Val
His Phe Thr Glu
His Phe Val Met
His Met Phe Val
His Met Val Phe
His Thr Glu Phe
His Thr Phe Glu
His Val Asp Tyr
His Val Phe Met
His Val Met Phe
His Tyr Asp Val
His Tyr Val Asp
Lys Cys Pro Trp
Lys Cys Trp Pro
Lys Glu Glu Gln
Lys Glu Gln Glu
Lys Pro Cys Trp
Lys Pro Trp Cys
Lys Gln Glu Glu
Lys Trp Cys Pro
Lys Trp Pro Cys
Met Phe His Val
Met Phe Val His
Met His Phe Val
Met His Val Phe
Met Val Phe His
Met Val His Phe
Asn Asp Arg Glu
Asn Asp Val Trp
Asn Asp Trp Val
Asn Glu Asp Arg
Asn Glu Arg Asp
Asn Arg Asp Glu
Asn Arg Glu Asp
Asn Val Asp Trp
Asn Val Trp Asp
Asn Trp Asp Val
Asn Trp Val Asp
Pro Cys Lys Trp
Pro Cys Gln Trp
Pro Cys Trp Lys
Pro Cys Trp Gln
Pro Lys Cys Trp
Pro Lys Trp Cys
Pro Gln Cys Trp
Pro Gln Trp Cys
Pro Trp Cys Lys
Pro Trp Cys Gln
Pro Trp Lys Cys
Pro Trp Gln Cys
Gln Ala Glu Trp
Gln Ala Trp Glu
Gln Cys Pro Trp
Gln Cys Trp Pro
Gln Asp Asp Arg
Gln Asp Arg Asp
Gln Glu Ala Trp
Gln Glu Glu Lys
Gln Glu Glu Gln
C20H32N6O11 (532.2128961999999)
Gln Glu Lys Glu
Gln Glu Gln Glu
C20H32N6O11 (532.2128961999999)
Gln Glu Trp Ala
Gln Lys Glu Glu
Gln Pro Cys Trp
Gln Pro Trp Cys
Gln Gln Glu Glu
C20H32N6O11 (532.2128961999999)
Gln Arg Asp Asp
Gln Trp Ala Glu
Gln Trp Cys Pro
Gln Trp Glu Ala
Gln Trp Pro Cys
Arg Asp Asp Gln
Arg Asp Glu Asn
Arg Asp Gly Trp
C23H32N8O7 (532.2393841999999)
Arg Asp Asn Glu
Arg Asp Gln Asp
Arg Asp Trp Gly
C23H32N8O7 (532.2393841999999)
Arg Glu Asp Asn
Arg Glu Asn Asp
Arg Gly Asp Trp
C23H32N8O7 (532.2393841999999)
Arg Gly Trp Asp
C23H32N8O7 (532.2393841999999)
Arg Asn Asp Glu
Arg Asn Glu Asp
Arg Gln Asp Asp
Arg Trp Asp Gly
C23H32N8O7 (532.2393841999999)
Arg Trp Gly Asp
C23H32N8O7 (532.2393841999999)
Ser Thr Tyr Tyr
Ser Tyr Thr Tyr
Ser Tyr Tyr Thr
Thr Glu Phe His
Thr Glu His Phe
Thr Phe Glu His
Thr Phe His Glu
Thr His Glu Phe
Thr His Phe Glu
Thr Ser Tyr Tyr
Thr Tyr Ser Tyr
Thr Tyr Tyr Ser
Val Asp His Tyr
Val Asp Asn Trp
Val Asp Trp Asn
Val Asp Tyr His
Val Phe His Met
Val Phe Met His
Val His Asp Tyr
Val His Phe Met
Val His Met Phe
Val His Tyr Asp
Val Met Phe His
Val Met His Phe
Val Asn Asp Trp
Val Asn Trp Asp
Val Trp Asp Asn
Val Trp Asn Asp
Val Tyr Asp His
Val Tyr His Asp
Trp Ala Ala Trp
Trp Ala Glu Gln
Trp Ala Gln Glu
Trp Ala Trp Ala
Trp Cys Lys Pro
Trp Cys Pro Lys
Trp Cys Pro Gln
Trp Cys Gln Pro
Trp Asp Gly Arg
C23H32N8O7 (532.2393841999999)
Trp Asp Asn Val
Trp Asp Arg Gly
C23H32N8O7 (532.2393841999999)
Trp Asp Val Asn
Trp Glu Ala Gln
Trp Glu Gln Ala
Trp Gly Asp Arg
C23H32N8O7 (532.2393841999999)
Trp Gly Arg Asp
C23H32N8O7 (532.2393841999999)
Trp Lys Cys Pro
Trp Lys Pro Cys
Trp Asn Asp Val
Trp Asn Val Asp
Trp Pro Cys Lys
Trp Pro Cys Gln
Trp Pro Lys Cys
Trp Pro Gln Cys
Trp Gln Ala Glu
Trp Gln Cys Pro
Trp Gln Glu Ala
Trp Gln Pro Cys
Trp Arg Asp Gly
C23H32N8O7 (532.2393841999999)
Trp Arg Gly Asp
C23H32N8O7 (532.2393841999999)
Trp Val Asp Asn
Trp Val Asn Asp
Trp Trp Ala Ala
Tyr Asp His Val
Tyr Asp Val His
Tyr Phe Phe Gly
Tyr Phe Gly Phe
Tyr Gly Phe Phe
Tyr His Asp Val
Tyr His Val Asp
Tyr Ser Thr Tyr
Tyr Ser Tyr Thr
Tyr Thr Ser Tyr
Tyr Thr Tyr Ser
Tyr Val Asp His
Tyr Val His Asp
Tyr Tyr Ser Thr
Tyr Tyr Thr Ser
Austalide D
Austalide E
NOMILINIC ACID
BENZOIC ACID, 4-[4-[(3R)-3-[[[2-OXO-2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]ETHYL]AMINO]CARBONYL]-1-PYRROLIDINYL]-1-PIPERIDINYL]-, METHYL ESTER
Sunitinib malate
C26H33FN4O7 (532.2333160000001)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D006133 - Growth Substances > D006131 - Growth Inhibitors
Bis(tert-butoxy)bis(1-methoxy-2-methyl-2-propoxy)hafnium(IV)
C18H40O6Hf (532.2290350000001)
4,6-bis(3-(2-ethylhexyl)thien-2-yl)thieno[3,4-c][1,2,5]thiadiazole
C28H40N2S4 (532.2074200000001)
Onvansertib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C177899 - PLK1 Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1,2,4-triazolo(4,3-a)pyridin-3-yl)ethynyl)-
C29H27F3N6O (532.2198328000001)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Ametantrone acetate
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents D000970 - Antineoplastic Agents
2-((2-((1-(2-(Dimethylamino)acetyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide
Ponatinib
C29H27F3N6O (532.2198328000001)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
(2R,6S)-2-amino-6-[[(4R)-4-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]-7-[[(2R)-1-[[(1R)-1-carboxyethyl]amino]-1-oxopropan-2-yl]amino]-7-oxoheptanoic acid
methyl (2S,3R,4S)-3-ethyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylate
4-[[2-(3-carboxypropanoyloxy)-1,4a-dimethyl-6-methylidene-5-[(E)-2-(5-oxo-2H-furan-4-yl)ethenyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-4-oxobutanoic acid
longipedumin A
A lignan isolated from the roots and stems of Kadsura longipedunculata and has been shown to exhibit inhibitory activity against HIV-1 protease.
N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide
(4-methoxyphenyl) N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
C31H36N2O6 (532.2573236000001)
N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(4-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-isoxazolecarboxamide
(4-methoxyphenyl) N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
C31H36N2O6 (532.2573236000001)
(4-methoxyphenyl) N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
C31H36N2O6 (532.2573236000001)
(4-methoxyphenyl) N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
C31H36N2O6 (532.2573236000001)
N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-4-fluoro-N-methylbenzenesulfonamide
2-[(3S,6aS,8R,10aS)-1-[(2-fluorophenyl)-oxomethyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-phenylphenyl)methyl]acetamide
(4-methoxyphenyl) N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate
C31H36N2O6 (532.2573236000001)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
IPN60090
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1?(GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2].
(8r,9r,10r)-5-hydroxy-3,4,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl (2e)-3-phenylprop-2-enoate
(1r,2r,3ar,5r,13r,13as)-1,3a,13-tris(acetyloxy)-2,5,8,8-tetramethyl-12-methylidene-4,9-dioxo-1h,3h,5h,13h,13ah-cyclopenta[12]annulen-2-yl acetate
(1s,2s,5s,6s,7s,9r,12r)-5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1s,2r,3s,5s,6s,8r,10s,11s,12r,14r,15s,16r,19s,21r)-6-(furan-3-yl)-3,12,16,19-tetrahydroxy-5,11,15-trimethyl-4-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate
11-isopropyl-4,7,14-trimethyl-18-(sec-butyl)-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol
(1s,2s,4r,5s,6r,7r,9r,12s)-5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(4s)-4-[(1e,3s)-3-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}but-1-en-1-yl]-4-hydroxy-3,5,5-trimethylcyclohex-2-en-1-one
3-(3,4-dihydroxyphenyl)-n-[4,7,10-trihydroxy-2,9,13-trimethyl-6-(2-methylpropyl)-14-oxo-1-oxa-5,8,11-triazacyclotetradeca-4,7,10-trien-3-yl]prop-2-enimidic acid
(1r,2s,4r,5r,6s,7s,9s,12r)-4,7-bis(acetyloxy)-2,12-dihydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl (2r,3s)-3-phenyloxirane-2-carboxylate
methyl (14e)-19-[(3,4-dimethoxybenzoyloxy)methyl]-14-ethylidene-18-oxa-2,12-diazahexacyclo[9.6.1.1⁹,¹⁵.0¹,⁹.0³,⁸.0¹²,¹⁷]nonadeca-3,5,7-triene-19-carboxylate
3-hydroxy-4,5,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2(7),3,5,13,18-hexaen-11-yl 3-phenylprop-2-enoate
(9s,10r)-4,5,14,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2(7),3,5,13,15-hexaen-3-yl (2e)-3-phenylprop-2-enoate
12-hydroxyamoorastatone
{"Ingredient_id": "HBIN000872","Ingredient_name": "12-hydroxyamoorastatone","Alias": "NA","Ingredient_formula": "C28H36O10","Ingredient_Smile": "CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C4C(=O)CC5C6=COC=C6)C)O)C)O)C)O)O","Ingredient_weight": "532.6 g/mol","OB_score": "NA","CAS_id": "152013-84-8","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9364","PubChem_id": "101672375","DrugBank_id": "NA"}
(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethylcyclohex-2-en-1-one
{"Ingredient_id": "HBIN010856","Ingredient_name": "(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethylcyclohex-2-en-1-one","Alias": "(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethyl-1-cyclohex-2-enone; (4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethyl-cyclohex-2-en-1-one","Ingredient_formula": "C25H40O12","Ingredient_Smile": "NA","Ingredient_weight": "532.58","OB_score": "30.24475007","CAS_id": "81425-28-7","SymMap_id": "SMIT13678","TCMID_id": "NA","TCMSP_id": "MOL012966","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
methyl 12-[1-(2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate
2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-15-yl acetate
(1r,2r,4s,16r,17s,18r,20s)-2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-18-yl acetate
(9r,10r,11s)-3-hydroxy-4,5,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2(7),3,5,13,18-hexaen-11-yl (2e)-3-phenylprop-2-enoate
(1s,2s,4r,5s,6s,9s,10s,11r,13r,14r,15s,18s,20r)-6-(furan-3-yl)-4,11,15,18-tetrahydroxy-5,10,14-trimethyl-3,8-dioxo-16-oxapentacyclo[12.3.3.0¹,¹³.0²,¹⁰.0⁵,⁹]icosan-20-yl acetate
(3s)-5-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r)-4-[(1s)-2-(hydroxymethyl)-6,6-dimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl]oxy}oxan-4-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
(1ar,3r,3ar,4r,5r,6r,7as)-4,5-bis(acetyloxy)-6-[(1s,6r)-6-(2-methoxy-2-oxoethyl)-1,5,5-trimethyl-4-oxocyclohex-2-en-1-yl]-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxirene-3-carboxylic acid
5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1r,2r,4r,5s,6s,7s,9s,12r)-4,5,12-tris(acetyloxy)-6-(hydroxymethyl)-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1r,2r,4s,16r,17s,18r,20s)-18-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-2-yl acetate
7,8,12-tris(acetyloxy)-2-hydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[3-(hydroxymethyl)-2-(3-methylbut-2-en-1-yl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenoxy]oxane-3,4,5-triol
(1r,2s,4r,5s,6r,7r,9s,12s)-4,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-5-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1r,2s,4r,5r,8r,9s,11r)-2-({[(1r,3s,5r,7s,8s,9s)-8-(acetyloxy)-9-hydroxy-2,4,6-trioxatricyclo[3.3.1.0³,⁷]nonan-5-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid
(1r,2r,4s,15s,16s,17r,20s)-2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-15-yl acetate
5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-8-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1r,2s,3r,4s,6r,7r,8r,9r,12s,13s)-9,12-bis(acetyloxy)-3-(chloromethyl)-3,13-dihydroxy-6-isopropyl-9,13-dimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl acetate
C26H41ClO9 (532.2438966000001)
(1r,2s,4r,5s,6r,7s,8r,9r)-5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
6-(furan-3-yl)-4,11,15,18-tetrahydroxy-5,10,14-trimethyl-3,8-dioxo-16-oxapentacyclo[12.3.3.0¹,¹³.0²,¹⁰.0⁵,⁹]icosan-20-yl acetate
(4r)-3,5,5-trimethyl-4-[(1e,3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}but-1-en-1-yl]cyclohex-2-en-1-one
(1r,7ar,9s,11br)-1-(acetyloxy)-9-[(s)-furan-3-yl(hydroxy)methyl]-5,5,7a,9,11b-pentamethyl-3,7-dioxo-hexahydro-1h-spiro[naphtho[2,1-c]oxepine-8,2'-oxirane]-3'-carboxylic acid
(8r,9s,10s)-5-hydroxy-3,4,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl (2e)-3-phenylprop-2-enoate
4-(3-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}but-1-en-1-yl)-4-hydroxy-3,5,5-trimethylcyclohex-2-en-1-one
2,9-bis(acetyloxy)-4,8,12,17-tetramethyl-5,16-dioxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadeca-6,12-dien-10-yl butanoate
(1s,2s,5s,6s,7s,9r,12r)-7,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate
4,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-5-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
2-(hydroxymethyl)-6-[3-(hydroxymethyl)-2-(3-methylbut-2-en-1-yl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenoxy]oxane-3,4,5-triol
5-{[3,5-dihydroxy-2-(hydroxymethyl)-6-({4-[2-(hydroxymethyl)-6,6-dimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl}oxy)oxan-4-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
(1s,2r,4s,5r,8r,9r,11s)-2-({[(1s,3r,5s,7r,8s,9s)-8-(acetyloxy)-9-hydroxy-2,4,6-trioxatricyclo[3.3.1.0³,⁷]nonan-5-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid
4,11,18-triisopropyl-7-methyl-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol
(4s,7r,8s,11s,15s,18s)-4,11,18-triisopropyl-7-methyl-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol
4,5-bis(acetyloxy)-6-[6-(2-methoxy-2-oxoethyl)-1,5,5-trimethyl-4-oxocyclohex-2-en-1-yl]-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxirene-3-carboxylic acid
(2e)-4-[(1r,5s,7r)-1-[(2s,3e,5r,6z)-7-chloro-5,9-dihydroxynona-3,6-dien-2-yl]-6-azaspiro[4.5]decan-7-yl]-2-methyl-n-(2-sulfoethyl)but-2-enimidic acid
C25H41ClN2O6S (532.2373716000001)
6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate
(1'r,2's,3r,3'r,4s,5'r,10's,11's,14's)-11'-(furan-3-yl)-3'-hydroxy-5'-(2-hydroxypropan-2-yl)-2',10'-dimethyl-6,13'-dioxo-12',15'-dioxaspiro[oxane-3,6'-tetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan]-4-yl acetate
(1r,2s,4r,5s,6r,7s,8r,9r)-4,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-5-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
4,5,14,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2(7),3,5,13,15-hexaen-3-yl 3-phenylprop-2-enoate
(1s,2s,5r,6r)-5,6-bis(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)-2-(piperidine-1-carbonyl)cyclohex-3-ene-1-carboximidic acid
C31H36N2O6 (532.2573236000001)
7,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate
(1'r,2s,2's,4's,6'r,7'r,11'r,12's,14's,16'r,20'r,23's,25'r)-12',14',25'-trihydroxy-4,7',22',22'-tetramethyl-3',10',17',21'-tetraoxaspiro[furan-2,9'-heptacyclo[12.11.0.0²,⁴.0²,¹¹.0⁶,¹¹.0¹⁶,²⁰.0¹⁶,²³]pentacosane]-5,18'-dione
(2s)-2-amino-n-[(2s)-1-{[(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-(1h-indol-3-yl)propanoyl]oxy}-3-(1h-indol-3-yl)-1-oxopropan-2-yl]propanimidic acid
11,13,24-trihydroxy-7,21,21-trimethyl-8-(4-methyl-5-oxo-2h-furan-2-yl)-3,9,16,20-tetraoxaheptacyclo[11.11.0.0²,⁴.0²,¹⁰.0⁶,¹⁰.0¹⁵,¹⁹.0¹⁵,²²]tetracosan-17-one
(3s)-3-(acetyloxy)-3-[(1r,2r,5r,6r,7r,10s,11s,14s)-11-(furan-3-yl)-5-(2-hydroxypropan-2-yl)-2,6,10-trimethyl-3,13-dioxo-12,15-dioxatetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan-6-yl]propanoic acid
12',14',25'-trihydroxy-4,7',22',22'-tetramethyl-3',10',17',21'-tetraoxaspiro[furan-2,9'-heptacyclo[12.11.0.0²,⁴.0²,¹¹.0⁶,¹¹.0¹⁶,²⁰.0¹⁶,²³]pentacosane]-5,18'-dione
5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1s,2r,4r,5r,6s,8r,10s,11s,12r,14r,15r,16r,19s,21r)-6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate
methyl (1s,12s,19s)-12-[(1s)-1-(7-methoxy-2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate
(1s,2r,5s,6s,7r,8r,9r,12r)-5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-8-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1s,2r,4s,5r,6r,7s,9r,12r)-5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
2-({[8-(acetyloxy)-9-hydroxy-2,4,6-trioxatricyclo[3.3.1.0³,⁷]nonan-5-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid
(2e,4e,6e,8e)-9-[(2s)-2-hydroxy-4-{[(2e,4e,6e)-1-hydroxy-8-methylnona-2,4,6-trien-1-ylidene]amino}-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl]-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)nona-2,4,6,8-tetraenimidic acid
18-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-2-yl acetate
11'-(furan-3-yl)-3'-hydroxy-5'-(2-hydroxypropan-2-yl)-2',10'-dimethyl-6,13'-dioxo-12',15'-dioxaspiro[oxane-3,6'-tetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan]-4-yl acetate
methyl (1r,12s,19r)-12-[(1r)-1-(7-methoxy-2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate
methyl 12-[1-(7-methoxy-2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate
2,6-bis(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)-5-(piperidine-1-carbonyl)cyclohex-3-ene-1-carboximidic acid
C31H36N2O6 (532.2573236000001)